The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen
- PMID: 40090622
- DOI: 10.1016/j.jtha.2025.03.006
The thrombin generation potential increases after feminizing gender-affirming hormone treatment, decreases after masculinizing gender-affirming hormone treatment, and is determined by the hormone treatment regimen
Abstract
Background: The effects of gender-affirming hormone therapy (GAHT) on the overall coagulation potential are not clarified. The global thrombin generation (TG) assay addresses the combined effect of coagulation factors and inhibitors.
Objectives: We aimed to investigate changes in TG after initiation of feminizing or masculinizing GAHT.
Methods: We included a cohort of 270 transgender women and 348 transgender men aged >17 years. The primary outcomes were TG variables (endogenous thrombin potential [ETP], peak TG, and TG lag time) measured at baseline and after 12 months of feminizing GAHT (3 groups of oral/transdermal estradiol and cyproterone acetate) or masculinizing GAHT (7 groups of intramuscular/transdermal testosterone).
Results: In transgender women, ETP and peak TG increased after oral and transdermal estradiol (P < .001), and the largest increase was after oral estradiol (ΔETP: 113 nmol/L × min, P = .011; Δpeak TG: 28 nmol/L, P = .009). In transgender men, ETP or peak TG decreased after 6 testosterone modalities (P < .05) except transdermal testosterone. The largest 12 months effect was seen in transgender men receiving gestagen at baseline compared with intramuscular testosterone (ΔETP: -199 nmol/L × min, P < .001; Δpeak TG: -38 nmol/L, P = .008) and transdermal testosterone (ΔETP: -216 nmol/L × min, P < .001; Δpeak TG: -40 nmol/L, P = .007). Lag time was prolonged for 6 testosterone modalities (P < .05), except in the subgroup receiving baseline gestagen, with no between-group differences.
Conclusion: Feminizing and masculinizing GAHT for 12 months affected coagulation in opposite directions. Feminizing GAHT was procoagulant, whereas masculinizing GAHT was anticoagulant. Of note, transdermal feminizing GAHT had the least pronounced procoagulant effect.
Keywords: blood coagulation; estradiol; hemostasis; testosterone; transgender persons.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interests There are no competing interests to disclose.
Similar articles
-
Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.Front Endocrinol (Lausanne). 2024 May 10;15:1086158. doi: 10.3389/fendo.2024.1086158. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38800485 Free PMC article.
-
Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.J Sex Med. 2022 May;19(5):864-871. doi: 10.1016/j.jsxm.2022.02.023. Epub 2022 Apr 1. J Sex Med. 2022. PMID: 35379590
-
Changes in affect variability after starting gender-affirming hormone therapy.Psychoneuroendocrinology. 2025 May;175:107408. doi: 10.1016/j.psyneuen.2025.107408. Epub 2025 Feb 21. Psychoneuroendocrinology. 2025. PMID: 40048874
-
Effect of gender-affirming hormone therapy on hair growth: a systematic review of the literature.Clin Exp Dermatol. 2023 Sep 19;48(10):1117-1127. doi: 10.1093/ced/llad203. Clin Exp Dermatol. 2023. PMID: 37311161
-
Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.Neurourol Urodyn. 2023 Jun;42(5):903-920. doi: 10.1002/nau.25097. Epub 2022 Nov 20. Neurourol Urodyn. 2023. PMID: 36403287 Review.
Cited by
-
Perioperative blood loss of sequential administration of hemocoagulase Agkistrodon and Tranexamic acid for primary total knee arthroplasty: a randomized controlled trial.J Orthop Surg Res. 2025 May 13;20(1):457. doi: 10.1186/s13018-025-05867-0. J Orthop Surg Res. 2025. PMID: 40355919 Free PMC article. Clinical Trial.
-
Emerging and accumulating safety signals for the use of estrogen among transgender women.Discov Ment Health. 2025 Jun 12;5(1):88. doi: 10.1007/s44192-025-00216-3. Discov Ment Health. 2025. PMID: 40506545 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous